Citations

Showing 10 of 108119 citations.

SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).
Guthrie, Katherine A. , Moran, César A. , Kulke, Matthew H. , Chan, Jennifer A. , LoConte, Noelle K. , Wolin, Edward M. , Mattar, Bassam, McDonough, Shannon, Chen, Helen X., Blanke, Charles D. , Höchster, Howard S. , LoConte, Noelle , Yao, James C. , Strosberg, Jonathan , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2015.33.15_suppl.4004 Get It

Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer.
Mohindra, Nisha , Kircher, Sheetal , Nimeiri, Halla , Benson, Al B. , Rademaker, Alfred , Alonso, E Ramos, Blatner, Nicole, Khazaie, Khashayarsha , Mulcahy, Mary F. , Alonso, Erin

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15281-e15281

10.1200/jco.2015.33.15_suppl.e15281 Get It

Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy ( Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
Picozzi, Vincent J. , Leach, Joseph L., Larson, Tim , Nishikubo, Carol Y., Anthony, Stephen P. , Lin, Bruce, Stoll, Amy C., Hoff, Daniel D. Von , Ramanathan, Ramesh K., Leach, Joseph, Larson, Tim, Bolejack, Vanessa

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15277-e15277

10.1200/jco.2015.33.15_suppl.e15277 Get It

Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
Kunzmann, Volker , Ramanathan, Ramesh K., Goldstein, David , Penenberg, Darryl, Ferrara, Stefano, Lu, Brian , Hoff, Daniel D. Von

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15299-e15299

10.1200/jco.2015.33.15_suppl.e15299 Get It

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.
Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel V., Höchster, Howard S. , Goldberg, Richard M. , Innocenti, Federico , Schilsky, Richard L. , Blanke, Charles D. , Stinzing, Sebastian, O’Neil, Bert H. , Niedzwiecki, Donna , Grothey, Axel , Mayer, Robert J. , Bertagnolli, Monica M. , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3585-3585

10.1200/jco.2015.33.15_suppl.3585 Get It

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.
Teufel, Michael, Schwenke, Susanne, Beckmann, Georg, Reischl, Joachim, Vonk, Richardus , Lenz, Heinz‐Josef , Jeffers, Michael , Wilhelm, Scott M., Wagner, Andrea, Laurent, Dirk, Kobina, Svetlana, Rutstein, Mark, Wirapati, Pratyaksha , Seidel, Henrik , Tabernero, Josep , Siena, Salvatore , Grothey, Axel , Cutsem, Eric Van , Wagner, Andrea, Guinney, Justin , Tejpar, Sabine

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3558-3558

10.1200/jco.2015.33.15_suppl.3558 Get It

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 tria
Thibodeau, Stephen N. , Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean‐Luc Van , Laurent‐Puig, Pierre , Laurent-Puig, Pierre , Taı̈eb, Julien , Malicot, Karine Le , Penault-Llorca, Frederique Madeleine , Bouché, Olivier , Shi, Qian , Tabernero, Josep , Sargent, Daniel J. , Alberts, Steven R. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3507-3507

10.1200/jco.2015.33.15_suppl.3507 Get It

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.
Smyrk, Thomas C. , Julié, Catherine , Zawadi, Ayman, Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean‐Luc Van , Laurent‐Puig, Pierre , Laurent-Puig, Pierre , Zaanan, Aziz , Shi, Qian , Taı̈eb, Julien , Alberts, Steven R. , Tabernero, Josep , Malicot, Karine Le , Sargent, Daniel J. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3506-3506

10.1200/jco.2015.33.15_suppl.3506 Get It

A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.
Ciombor, Kristen K. , Edenfield, William J. , O’Dwyer, Peter J. , Becerra, Carlos , Larson, Tim , Manoharan, Divya , Li, Wei , Borodyansky, Laura, Li, Chiang, Hubbard, Joleen M. , Larson, Tim, Spira, Alexander I. , Grothey, Axel , Manoharan, Divya, Li, Youzhi , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3617-3617

10.1200/jco.2015.33.15_suppl.3617 Get It